SCHEMBL4907499

SCHEMBL4907499

CCOC(=O)c1ccc2c(c1)ncn2CCC(C)(C)NC(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
SIRT2 Q8IXJ6 1/20 0.39
SIRT1 Q96EB6 1/20 0.39
TP53 P04637 1/20 0.39
F10 P00742 2/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
RIPK1 Q13546 1/20 0.39
RIPK3 Q9Y572 1/20 0.39
HDAC1 Q13547 1/20 0.39
RECQL P46063 1/20 0.38
MAPK10 P53779 1/20 0.38
GAA P10253 1/20 0.38
NLRP3 Q96P20 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911401 0.92 NPC1 (0.45) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL4887298 0.84 ALDH1A1 (0.39) NPC1RAB9ASMN1; SMN2TP53MAPT
SCHEMBL4914665 0.83 ALDH1A1 (0.40) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL4640617 0.83 ALDH1A1 (0.40) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL4890412 0.82 ALDH1A1 (0.39) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL4913399 0.82 NPC1 (0.47) NPC1RAB9AMEN1KMT2AHPGD
SCHEMBL14800208 0.80 HPGD (0.53) NPC1RAB9AMEN1KMT2AHPGD
SCHEMBL4915386 0.79 CRHBP (0.35) MEN1KMT2AHPGDSMN1; SMN2MAPT
SCHEMBL4641222 0.79 MTNR1A (0.45) NPC1RAB9AMEN1KMT2AHPGD
SCHEMBL4768461 0.79 ALDH1A1 (0.38) NPC1RAB9AHPGDSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 NPC1 1596/4885RAB9A 1706/4885MEN1 2066/4885
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance ADRB3, ADRB1, ADRA1B NPC1 1873/4885RAB9A 1943/4885MEN1 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.